(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/202223 A1

(51) International Patent Classification:
C12N 15/115 (2010.01) *G01N 33/543* (2006.01)
G01N 33/574 (2006.01)

(21) International Application Number:
PCT/EP2025/058171

(22) International Filing Date:
25 March 2025 (25.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
24167684.0 28 March 2024 (28.03.2024) EP
25151124.2 10 January 2025 (10.01.2025) EP

(71) Applicants: **OSPEDALE SAN RAFFAELE S.R.L.** [IT/IT]; Via Olgettina, 60, 20132 Milano (MI) (IT). **ALMA MATER STUDIORUM - UNIVERSITÀ DI BOLOGNA** [IT/IT]; Via Zamboni 33, 40126 Bologna (IT).

(72) Inventors: **COMES FRANCHINI, Mauro**; ALMA MATER STUDIORUM - UNIVERSITÀ DI, BOLOGNA, Via Zamboni 33, 40126 Bologna (IT). **LOCATELLI, Erica**; ALMA MATER STUDIORUM - UNIVERSITÀ DI, BOLOGNA, Via Zamboni 33, 40126 Bologna (IT). **TORTORELLA, Silvia**; ALMA MATER STUDIORUM - UNIVERSITÀ DI, BOLOGNA, Via Zamboni 33, 40126 Bologna (IT). **ALFANO, Massimo**; Ospedale San Raffaele S.r.l., Via Olgettina, 60, Italy, 20132 Milano (IT). **VENEGONI, Chiara**; Ospedale San Raffaele S.r.l., Via Olgettina, 60, Italy, 20132 Milano (IT). **LOCATELLI, Irene**; Ospedale San Raffaele S.r.l., Via Olgettina, 60, Italy, 20132 Milano (IT).

(74) Agent: **PACE NAPOLEONE, Maria** et al.; De Simone and Partners S.r.l., Via Giulio Caccini 1, 00198 Rome (IT).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2025/202223 A1

(54) Title: MULTIFUNCTIONAL SYSTEM

(57) Abstract: The invention is directed to a multifunctional system bearing a ligand capable of recognizing tumor cells or tumor-associated or inflammation-associated component and linked to a metal nanoparticle. More specifically, the multifunctional system of the invention comprises a nucleotide aptamer or a variant thereof that binds to the alpha 5 subunit of integrin and a metal nanoparticle, wherein said aptamer optionally comprises at least one modification capable of enhancing nuclease resistance thus providing a molecule with high stability for example in human urine.